Glycans News and Research

RSS

Scientists reprogram a common bacterium to make designer sugar-based drug

Envisioning an animal-free drug supply, scientists have -; for the first time -; reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals.

2 Mar 2021

Researchers study how glycans activate SARS-CoV-2

One thing that makes SARS-CoV-2, the virus that causes COVID-19, elusive to the immune system is that it is covered in sugars called glycans.

25 Feb 2021

Full characterization of mammalian-produced SARS-CoV-2 receptor binding domains

A research paper recently uploaded to the preprint server bioRxiv by Dominguez-Vega et al. (23rd Feb, 2021) describes an in-depth structural analysis of the RBD of the spike protein expressed in mammalian Chinese hamster ovary (CHO) cells and human embryonic kidney (HEK293) cells, providing a new understanding of protein structure and function.

24 Feb 2021

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

By analyzing the cryoEM structures of antibodies against the SARS-CoV-2 virus, researchers report that the neutralizing capabilities of two antibodies are not affected by new strains as these antibodies target regions of the virus away from the ACE2 binding regions.

23 Feb 2021

Glycan switch may explain why SARS-CoV-2 causes such variable symptoms

Researchers in Portugal have provided evidence that might explain why infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes mild or even asymptomatic illness in some individuals, but severe coronavirus disease 2019 (COVID-19) in others.

23 Feb 2021

Study provides new information about the structure of prion proteins

Prion diseases are a group of rapidly progressive, fatal and infectious neurodegenerative disorders affecting both humans and animals: Bovine Spongiform Encephalopathy (BSE) or 'mad cow' disease is one of the most famous since in 1996 scientists found that the agent responsible for the disease in cows, is the same agent responsible for the so-called variant Creutzfeldt-Jakob Disease (vCJD), a disease affecting humans.

20 Feb 2021

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines

The mapping of O-glycosites requires instruments that can support electron transfer dissociation (ETD) fragmentation. In a new study published on the bioRxiv preprint server, researchers report their results on whether O-glycosylation patterns affect immunogens for vaccine development.

18 Feb 2021

A glycan controls how SARS-CoV-2’s spike protein opens, study finds

Using simulations, a team of researchers in the U.S. found that the glycan at position N343 of the SARS-CoV-2 spike protein’s receptor-binding domain (RBD) helps in its opening. A mechanism that aids its binding to the host cell receptor.

18 Feb 2021

The origin of SARS-CoV-2 furin cleavage site remains a mystery

A new study discusses the origin of the furin cleavage site on the SARS-CoV-2 spike protein, which is responsible for the virus’s relatively high infectivity compared to relatives in the betacoronavirus subgenus.

17 Feb 2021

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

A new study provides direct evidence that the oligosaccharides attached to the viral surface spike protein are essential for viral infection, offering new approaches to preventive and therapeutic drugs.

9 Feb 2021

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

A new study server reports highly protective neutralizing monoclonal antibodies against the SARS-CoV-2.

4 Feb 2021

New platform for detecting and monitoring SARS-CoV-2 antibody responses

Researchers in the U.S. have released a new study that describes a powerful but inexpensive tool designed to detect and monitor specific antibodies to SARS-CoV-2 over time.

1 Feb 2021

Crystal structures of nanobodies could aid the design of COVID-19 therapies

Researchers at the National Institutes of Health in Bethesda, Maryland, have shown how certain synthetic nanobodies bind to the agent that causes coronavirus disease 2019 (COVID-19) – a development that could help inform the design of therapies.

31 Jan 2021

Biliverdin shields SARS-CoV-2 from host antibody response, study finds

A team of international scientists has recently revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts with two heme metabolites, bilirubin and biliverdin, to escape the antibody-mediated host immune responses.

27 Jan 2021

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

Researchers develop a novel, simple and affordable method for N-glycan fingerprinting based on enzymatic fluorescent glycan labeling and electrophoresis. This new method may help us understand important changes in glycosylation in the SARS-CoV-2 spike protein – something which could inform future therapeutic research.

20 Jan 2021

Study identifies features of potent SARS-CoV-2 neutralizing antibodies

Researchers at Columbia University have provided important insights into features of viral binding and recognition within a class of potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Jan 2021

Antigenic "supersite" could improve design of COVID-19 vaccines

Researchers in the United States have defined an antigenic “supersite” within the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have important implications for the design of vaccines to protect against coronavirus disease 2019 (COVID-19).

12 Jan 2021

Scientists demonstrate a promising strategy for treating lymphomas

Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes.

16 Dec 2020

N-Glycosylation sites may contribute to spike-mediated invasion by SARS-CoV-2

The sugar residues decorating the spike (S) protein of SARS-CoV-2 are essential to the viral-receptor binding.

3 Dec 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020